Blog

Why quality and traceability matter in coagulation reagents for IVD

Why quality and traceability matter in coagulation reagents for IVD

Coagulation diagnostics sit underneath some of the most common tests in medicine: prothrombin time (PT), activated partial thromboplastin time (aPTT) and anticoagulant monitoring. They are part of the wider in vitro diagnostics (IVD) field, alongside related tests such as coagulase assays, which detect bacterial coagulase activity to tell organisms apart, most notably coagulase-positive Staphylococcus aureus. All of them depend on biologically derived reagents.

That dependence is under pressure: the COVID-19 pandemic exposed real weaknesses in global IVD supply chains, with shortages of reagents and materials that cut testing capacity and disrupted diagnostic workflows. At the same time, regulators are asking for more. The FDA's IVD regulation and the EU's In Vitro Diagnostic Regulation (IVDR) both tighten requirements for performance, safety, transparency and traceability, with more technical documentation expected from manufacturers. And the industry relies on a small pool of suppliers, which makes shortages and variability more likely.

For coagulation reagents specifically, a manufacturing disruption or a cold-chain failure interrupts validation studies, lot qualification and production schedules. Assay performance depends on consistent reagents, so this is a risk that runs through development and manufacturing and makes reproducibility and compliance harder to guarantee.

So two questions: how do these pressures affect IVD assay development, and how far can quality, traceability and sourcing strategy reduce the risk?

What reagent variability costs

Many everyday coagulation reagents, rabbit brain cephalin, rabbit brain acetone powder and other acetone powders, are biologically derived and therefore variable. Differences in sourcing and processing, and lot-to-lot inconsistency, feed straight into assay performance. A change in reagent composition shifts clotting times in PT and aPTT and undermines the reliability of coagulase assays, so results drift between runs and between batches.

For IVD assay development this is expensive. Validation and lot qualification need a high degree of consistency; variability means failed validation runs, repeat testing, and delays in method transfer or scale-up. At the regulatory level, inconsistent reagent performance invites audit findings, extra data requests and slower approvals, at a time when the requirements are already getting stricter.

Consistency and traceability in every batch

The answer is consistency built on controlled quality systems and standardized processes. It starts with standardized sourcing and processing under US standards, with a real commitment to animal welfare. Every lot should be tested against defined specifications, with a Certificate of Analysis (CoA) and conformity documentation as the formal record.

Responsible sourcing and humane handling matter for the animals and for the reagent, because a stable, well-cared-for source is a consistent one.

Look for suppliers that run a real Quality Management System, ISO 9001:2015 for instance, so that reproducibility and control are structured into production rather than left to habit. Full visibility into materials and processes supports root cause analysis, audit readiness and regulatory compliance, and it lowers the chance you will need to revalidate.

What to look for in a supplier

Choosing a coagulation reagent manufacturer is one of the bigger levers you have for reducing risk. When you compare suppliers, weigh the following (Table 1).

  • Quality and consistency. ISO-certified systems and reliable lot-to-lot performance.
  • Traceability. Detailed documentation and batch traceability.
  • Sourcing and production. Standardized, ethical sourcing of biological materials.
  • Supply reliability. The ability to deliver consistent volumes, with bulk availability, so you can stay on one lot.
  • Supply chain considerations. Diversify suppliers where possible and prioritize stable, US-based sourcing to reduce disruption risk.

Table 1: Criteria for evaluating a reliable coagulation reagent manufacturer for IVD assay development.

Suppliers that meet these criteria support consistent assay performance, fewer delays in validation and manufacturing, and lower operational and regulatory risk. As a short checklist: an ISO 9001:2015 certified QMS and standardized processes; rigorous lot testing; full traceability with CoA and conformity documentation; US-based manufacturing for supply stability; and bulk capability for long-term lot consistency. These are the standards we hold ourselves to at Pel-Freez.

Variability in coagulation reagents creates risk across validation, production and regulatory compliance, and regulatory pressure and supply instability make it worse. Strong quality systems, full traceability and reliable sourcing partnerships are how you manage it, and they make IVD assay development faster and more predictable in the process.

If you are working on assay development or diagnostic kit manufacturing and want to talk through quality and traceability in your reagent supply, contact us.